US FDA approves Mirum Pharma's genetic disorder drug
21/02/2025 16:54
Feb 21 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved Mirum Pharmaceuticals' MIRM.O drug to treat a type of rare disorder, which affects the body's ability to metabolize fats known as cholesterol. (Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar) ((Sriparna.Roy@thomsonreuters.com))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX